New drug duo aims to shrink enlarged spleens in blood cancer patients
NCT ID NCT06245941
Summary
This study tested a combination of two oral drugs, TQ05105 and TQB3909, for adults with moderate-to-high risk myelofibrosis, a serious bone marrow cancer. The main goals were to find a safe dose and see if the treatment could reduce spleen size and ease symptoms. The trial was terminated early and involved 21 participants across multiple centers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hennan Cancer Hospital
Zhengzhou, Henan, 450003, China
-
People's Hospital of Tianjin
Tianjin, Tianjin Municipality, 300122, China
-
The First Affiliated Hospital Zhejiang University School Of Medicine
Hangzhou, Zhejiang, 310003, China
-
The Second People's Hospital of Hefei
Hefei, Anhui, 230012, China
-
Xijing Hospital of the Fourth Military Medical University
Xi'an, Shaanxi, 710032, China
Conditions
Explore the condition pages connected to this study.